BIOGEN INC. - 10 Jan 2025 SCHEDULE 13D Report for Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE)

Filing Manager
BIOGEN INC.
Reporting Manager
BIOGEN INC.
Security
Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol
SAGE
Shares outstanding
61,190,912 shares
Disclosed Ownership
6,241,473 shares
Ownership
10%
Form type
SCHEDULE 13D
Filing time
10 Jan 2025, 17:34:57 UTC
Date of event
10 Jan 2025
Next filing
21 Jul 2025
SEC
View on sec.gov

Quoteable Key Fact

"BIOGEN INC. disclosed 10% ownership in Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE) on 10 Jan 2025."

Quick Takeaways

  • BIOGEN INC. filed SCHEDULE 13D for Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE).
  • Disclosed ownership: 10%.
  • Date of event: 10 Jan 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 10 Jan 2025, 17:34.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOGEN INC. 10% 6,241,473 0 6,241,473 /s/ Michael Dambach Michael Dambach, Treasurer 0000875045
Biogen MA Inc. 10% 6,241,473 0 6,241,473 /s/ Michael Dambach Michael Dambach, Treasurer